top of page
Single_Cell_Gradient_9a.png
Search

Biocentury Emerging Company Profile  -  Accession: precisely targeted oncolytic viruses

  • Writer: davidtokley
    davidtokley
  • Nov 29, 2022
  • 1 min read

Updated: Jan 3, 2023

Bent Jakobsen’s newest biotech is replacing the virus’ natural tropisms with an integrin-based cancer targeting mechanism - read the article by Richard Guy, Biopharma Analyst, here >






 
 
 

Comments


bottom of page